Subject Area

Internal Medicine

Article Type

Original Study


Objectives: to investigate the level of cystatin C in T2DM patients with obesity.

Background: the risk of type 2 diabetes (T2DM) increases many folds in association with obesity. Cystatin C is an early marker for nephropathy and it can predict neuropathy, retinopathy, and arterial sclerosis apart from renal function.

Methods: it is a cross-sectional and observational study. A total of 561 subjects were divided into group A: 130 obese patients with no T2DM, group B: 155 T2DM with obesity, group C: 146 T2DM patients with no obesity attended to Internal Medicine Department in Menoufia University Hospital, and group D:130 healthy persons as a control group during the period from November 2020 to December 2021. All participants were subjected to full history taking, clinical examination, and estimation of serum Cystatin C using enzyme-linked immunosorbent assay (ELISA). Non-alcoholic fatty liver disease fibrosis score and body mass index (BMI) were assessed for the patients.

Results: serum Cystatin C level, non-alcoholic fatty liver disease fibrosis scoreand BMI were significantly increased among the diabetic obese group than other groups (P

Conclusion: Serum cystatin C was positively correlated with obesity. Therefore, it can be counted as an early predictor of metabolic syndrome.